Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
Cell Impact has been awarded gold medal by EcoVadis
KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was…
Hyundai Motor Group and Pyeongtaek City Collaborate to Advance CarbonNeutral Hydrogen Port Development
Hyundai Motor Group signs a multilateral MoU with Pyeongtaek City and key…
Cell Impact and thyssenkrupp Automation Engineering have entered a cooperation agreement
KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have…
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Two oral and seven poster presentations further support the CARVYKTI® research in…
Cellectis to Report Third Quarter Financial Results on November 7, 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext…
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc.…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…